Shares were sold at prices ranging from $1.23 to $1.37 per share, for a weighted average selling price of $1.2936 per share. Following these transactions, Vieceli retains ownership of 160,493 shares in the company. The sale was made to cover tax withholding liabilities related to the grant of restricted stock units granted earlier in the year and was not a discretionary trade by Vesely. While the company maintains a strong liquidity position with a current ratio of 13.4 and more cash than debt on its balance sheet, InvestingPro Subscribers can access detailed insider trading patterns and over 10 additional exclusive insights into FX's financial condition and market position. While the company maintains a strong liquidity position with a current ratio of 13.4 and more cash than debt on its balance sheet, InvestingPro Subscribers can access detailed insider trading patterns and over 10 additional exclusive insights into QSI's financial health and market position.
Shares were sold at prices ranging from $1.23 to $1.37 per share, for a weighted average selling price of $1.2936 per share. Following these transactions, Vieceli retains ownership of 160,493 shares in the company. The sale was made to cover tax withholding liabilities related to the grant of restricted stock units granted earlier in the year and was not a discretionary trade by Vesely.
In other recent news, Quantum-Si Incorporated reported important developments. The company has seen its revenues grow by 232% over the past year, attributed to its innovative solutions in protein sequencing technology. Quantum-Si's third-quarter earnings fell short of expectations with revenue of about $787,000 due to delays in hardware sales, but it expects a strong quarter with revenue expected to exceed the $1 million mark.
The company also announced a significant workforce reduction and restructuring to streamline operations. Additionally, Quantum-Si has regained compliance with NASDAQ's minimum offering price requirements, resolving a potential listing issue.
In terms of product development, Quantum-Si announced early access to ProteoVue, a tool designed to aid proteomics research. The company also partnered with NVIDIA (NASDAQ:) to enhance its proprietary proteomics platform, Proteus™, using NVIDIA's artificial intelligence and accelerated computing capabilities.
HC Wainwright maintained a Buy rating on Quantum-Si and increased the price target to $5.50, following Quantum-Si's recent Investor Day event. These are the latest developments related to Quantum-Si Incorporated.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
